Natera/$NTRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Ticker
$NTRA
Sector
Primary listing
Employees
6,138
Headquarters
Website
Natera Metrics
BasicAdvanced
$39bn
-
-$1.64
1.57
-
Price and volume
Market cap
$39bn
Beta
1.57
52-week high
$288.04
52-week low
$134.85
Average daily volume
1.4m
Financial strength
Current ratio
2.959
Quick ratio
2.697
Long term debt to equity
8.171
Total debt to equity
12.698
Interest coverage (TTM)
-80.14%
Profitability
EBITDA (TTM)
-267.577
Gross margin (TTM)
65.07%
Net profit margin (TTM)
-9.05%
Operating margin (TTM)
-12.68%
Effective tax rate (TTM)
20.91%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-9.32%
Return on equity (TTM)
-15.02%
Valuation
Price to revenue (TTM)
15.23
Price to book
22.14
Price to tangible book (TTM)
31.03
Price to free cash flow (TTM)
532.636
Free cash flow yield (TTM)
0.19%
Free cash flow per share (TTM)
0.517
Growth
Revenue change (TTM)
36.59%
Earnings per share change (TTM)
10.47%
3-year revenue growth (CAGR)
42.30%
10-year revenue growth (CAGR)
28.43%
3-year earnings per share growth (CAGR)
-32.56%
10-year earnings per share growth (CAGR)
-1.17%
What the Analysts think about Natera
Analyst ratings (Buy, Hold, Sell) for Natera stock.
Natera Financial Performance
Revenues and expenses
Natera Earnings Performance
Company profitability
Natera News
AllArticlesVideos
Natera Submits Signatera™ to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Business Wire·12 hours ago
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
Business Wire·2 weeks ago
Finalized MolDx LCD Includes Expanded Coverage for Natera's Prospera™ Portfolio
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.